A review on the current status and development of Parkinson's clinical drugs

Yuxin Huang

doi:10.1117/12.2692219

7 September 2023 A review on the current status and development of Parkinson's clinical drugs

Yuxin Huang

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 127892Z (2023) https://doi.org/10.1117/12.2692219
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

Alzheimer's is known as the most prevalent neurological condition while Parkinson's is known as the second. Common symptoms of Parkinson's include slowness of movement, muscle rigidity, and resting tremors. There are several non-motor symptoms as well and some of them may appear before the motor issues. After developing Parkinson's disease, dopaminergic neurons in the substantia nigra gradually die, causing a pathway to malfunction and recognizable motor issues. Unfortunately, very little about the molecular processes that lead to the death of dopaminergic neurons is studied. To understand the current research progress and find new research directions, the author sorted out the drugs currently used in clinical practice and summarized the clinical stages and treatment strategies of the drugs under study by searching relevant literature in PubMed. Conclusions can be drawn that the related research is progressing steadily and new breakthroughs are being made.

Citation Download Citation

Yuxin Huang "A review on the current status and development of Parkinson's clinical drugs", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 127892Z (7 September 2023); https://doi.org/10.1117/12.2692219

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available